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Background: The MTHFR (methylenetetrahydrofolate reductase) rs1801133
polymorphism leads to higher circulating levels of homocysteine, which is related
to several liver diseases. We aimed to evaluate the relationship between MTHFR
rs1801133 polymorphism and liver fibrosis progression in HCV-infected patients.
Methods: We conducted a preliminary retrospective cohort study in 208 non-cirrhotic
HCV-infected patients. These subjects had at least two liver stiffness measurements
(LSM), which were assessed using transient elastography, and no patient had cirrhosis
at baseline. We analyzed the association between MTHFR rs1801133 and outcome
variables using Generalized Linear Models.
Results: HCV-infected patients were 47 years old, around 54% were males, a low
frequency of high alcohol intake (13.5%) or prior use of intravenous drugs (10.1%). A
total of 26 patients developed cirrhosis (LSM1 ≥ 12.5) during a median follow-up of 46.6
months. The presence of the rs1801133C allele showed an inverse association with
the LSM2/LSM1 ratio (adjusted AMR = 0.90; 95%CI = 0.83–0.98; p = 0.020) and the
cirrhosis progression (adjusted OR = 0.43; 95%CI = 0.19–0.95; p = 0.038). Besides,
rs1801133 CT/CC genotype had an inverse association with the LSM2/LSM1 ratio
(adjusted AMR = 0.80; 95%CI = 0.68–0.95; p = 0.009) and the cirrhosis progression
(adjusted OR= 0.21; 95%CI = 0.06–0.74; p = 0.015).
Conclusions: MTHFR rs1801133C allele carriers presented a diminished risk of liver
fibrosis progression and development of cirrhosis than rs1801133 T allele carriers. This
statement supports the hypothesis that MTHFR rs1801133 polymorphism appears to
play a crucial role in chronic hepatitis C immunopathogenesis.
Keywords: chronic hepatitis C, liver stiffness measure, hepatic fibrosis, cirrhosis, MTHFR (C677T), SNPs (single
nucleotide polymorphism)
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INTRODUCTION
According to the world health organization, viral hepatitis is a
significant public health problem that causes 1.34 million deaths
per year due to chronic liver disease (720,000 by cirrhosis) and
primary liver cancer (47,000 by hepatocellular carcinoma) (1).
Globally, around 71 million people suffer chronic hepatitis C
(CHC) and the development of the previously described events
is frequent (2, 3), even after a sustained virological response
(SVR) to treatment with direct-acting antivirals (DAAs) (4, 5).
The pathogenic mechanisms involved in the progression of
fibrosis and cirrhosis depends, among others, on the genetic
background of individuals, including several single nucleotide
polymorphisms (SNPs) (6, 7).
The staging of liver fibrosis provides essential clinical
information that allows the adequate management and prognosis
of CHC patients (8). The liver biopsy has been used to grade the
necroinflammatory activity and to stage fibrosis, together with
rating scales like METAVIR, which stratify fibrosis as: (i) F0, no
fibrosis; (ii) F1, mild fibrosis; (iii) F2, significant fibrosis; (iv) F3,
advanced fibrosis; and (v) F4, cirrhosis (9). Nevertheless, non-
invasive approaches, as the transient elastography or FibroScan,
have been widely used to the liver fibrosis assessment, with
excellent accuracy in advanced fibrosis and cirrhosis (10). In
this context, the evaluation of liver stiffness measurement (LSM),
an intrinsic physical property of liver parenchyma, provides
quantitative data that correlates with fibrosis stage in CHC (11).
The methylenetetrahydrofolate reductase (MTHFR) gene
encodes an enzyme that plays an important role in the folate
metabolism, allowing the conversion from homocysteine to
methionine (12). The rs1801133 SNP (also named C677T) is a
non-synonymous variant A (Ala) > V (Val) (missense variant)
(13). The substitution A > V in the aminoacid 222 (Ala222Val)
produces a decrease of the activity of MTHFR protein and
an elevation of plasma homocysteine levels (13). Hyper-
homocysteinemia was related to several diseases, including
hepatocellular carcinoma, steatosis, and cirrhosis (14–16), and
also the development of liver fibrosis in CHC (17). There
are a few articles published about MTHFR rs1801133 in CHC
patients. MTHFR C677T polymorphism has been related to
hepatic steatosis (18) and development of liver fibrosis (16, 17),
but no association was found in other articles in patients infected
with HCV (19–21). Additionally, this polymorphism could also
be related to a direct profibrogenic effect, modifying the action of
proteins implicated in the degradation of collagen (22).
The main objective in the current study was to investigate
the association of MTHFR rs1801133 polymorphism with the
progression of liver fibrosis and cirrhosis development, evaluated
by LSM, in patients with CHC.
Abbreviations: CHC, chronic hepatitis C; HCV, hepatitis C virus; DAAs, direct-
acting antivirals; SNPs, single nucleotide polymorphisms; LSM, liver stiffness
measurement; MTHFR, methylenetetrahydrofolate reductase; F4; LSM1 ≥ 12.5
kPa, cirrhosis; LSM1, baseline LSM; LSM2, final LSM; 1LSM, increase of LSM;
GLM, generalized linear models; AMR, arithmetic mean ratio; OR, odds ratio;
SPSS, statistical package for the social sciences; IBS, Iberian population in Spain.
MATERIALS AND METHODS
Study Population
A preliminary retrospective study was performed in 208
patients from the Hospital Virgen de la Salud (Toledo, Spain).
All patients suffered from chronic hepatitis C and were
enrolled between 2008 and 2016, as previously described (see
Supplementary Figure 1) (23).
We selected the patients according to these criteria: (i)
available DNA sample; (ii) detectable plasma HCV RNA at
baseline and during follow-up; and (iii) baseline LSM (LSM1)
and final LSM (LSM2) available with a separation of 12 months
at least. Regarding the exclusion criteria, we considered: (i) liver
cirrhosis at baseline (F4; LSM1 ≥ 12.5 kPa); (ii) coinfection with
human immunodeficiency virus or hepatitis B virus; and (iii)
autoimmune liver disease.
The study was conducted with the consent of all patients and
following the 1975 Declaration of Helsinki. It was approved by
the Institutional Review Board of the Instituto de Salud Carlos
III (“Comité de Ética de la Investigación y Bienestar Animal”
–April 4, 2013).
Clinical Data
As described previously (24), clinical and epidemiological data
were collected from medical records. These data included
virological, demographic, clinical, and laboratory data. Clinical
guidelines available at that time (25, 26) were followed to perform
the clinical management of patients during the follow-up.
At baseline, we only included non-responder patients
(patients treated for HCV infection before the study), although
it was possible to administrate the HCV therapy before or
after being included in the study. During the follow-up, the
monitoring was stopped when a patient started the HCV therapy
and obtained an SVR.
DNA Genotyping
Genomic DNA obtained from 200 microliters of peripheral
blood was extracted using the QIAsymphony DNA Mini Kit
(Qiagen, Hilden, Germany). MTHFR rs1801133 polymorphism
was genotyped at the CeGen (Spanish National Genotyping
Center; http://www.cegen.org/). Agena Bioscience’s MassARRAY
platform (San Diego, CA, USA) and the iPLEX R© Gold assay
design system were used according to the method described by
Gabriel et al. (27).
Evaluation of Liver Fibrosis
The hepatic fibrosis was evaluated using the transient
elastography (FibroScan, Echosens, Paris, France), by a
trained hepatologist and with a single machine, as we previously
described (24). LSM has a range of 2.5 to 75 kilopascals (kPa).
When the interquartile-range-to-median ratio for at least 10
successful measurements was <0.30, it was considered reliable.
The cut-offs of LSM proposed by Castera et al. were followed
for the stratification of patients: (i) <7.1 kPa (F0–F1—absence
or mild fibrosis); (ii) 7.1–9.4 kPa (F2—significant fibrosis);
(iii) 9.5-12.4 kPa (F3—advanced fibrosis); and (iv) ≥12.5 kPa
(F4—cirrhosis) (28).
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TABLE 1 | Epidemiological and clinical characteristics of HCV-infected patients at baseline.
MTHFR rs1801133 polymorphism
Characteristic All patients TT CT CC P-value
No. 208 29 112 67
Male 112 (53.8%) 14 (48.33%) 65 (58%) 33(49.3%) 0.423
Age (years) 47.1(41.5; 57.6) 46.96 (39.5; 57.3) 46.85 (41.3; 55.4) 48.2 (42.6; 60.8) 0.988
Time of HCV infection (years) 8.2 (3.2; 13.2) 7.8 (3.3; 11.9) 8.1 (2.9; 13.3) 9 (2.7; 13.3) 0.959
High alcohol intake 28 (13.5%) 1 (3.4%) 20 (17.9%) 7 (10.4%) 0.087
Prior injection drug use 21 (10.1%) 1 (3.4%) 18 (16.1%) 2 (3%) 0.008
HCV genotype (n = 204)
1 174 (85.3%) 26 (92.9%) 90 (82.6%) 58 (86.6%) 0.366
3 14 (6.9%) 1 (3.6%) 9 (8.3%) 4 (6%) 0.641
4 15 (7.4%) 1 (3.6%) 9 (8.3%) 5 (7.5%) 0.698
5 1 (0.5%) 0 (0.0%) 1 (0.9%) 0 (0%) -
Prior failed IFN therapy 47 (22.6%) 6 (20.7%) 26 (23.2%) 15 (22.4%) 0.958
Baseline LSM (kPa) 6.1 (5.2; 7.7) 6.6 (5.2; 7.5) 6.1 (5.2; 7.7) 5.9 (5.1; 7.7) 0.961
F0–F1 (<7.1 kPa) 149 (71.6%) 21 (72.4%) 79 (70.5%) 49 (73.1%) 0.928
F2 (7.1–9.4 kPa) 38 (18.3%) 5 (18.2%) 22 (19.6%) 11 (16.4%) 0.873
F3 (9.5–12.4 kPa) 21 (10.1%) 3 (6.8%) 11 (9.8%) 7 (10.4%) 0.904
Statistics: Values are expressed as absolute numbers (%) or median (percentile 25; percentile 75). P-values were estimated with Chi-square test for categorical variables and
non-parametric Mann-Whitney U test for continuous variables.
HCV, hepatitis C virus; IFN, interferon; kPa, kilopascal; LSM, liver stiffness measure; MTHFR, methylenetetrahydrofolate reductase.
Significant differences are shown in bold.
Outcome Variable
We analyzed how LSM values changed during the follow-up,
considering: (i) the date of the first LSM (LSM1) and (ii) the
date of the last LSM (LSM2), or the date when the HCV therapy
started in responder patients who cleared HCV infection. For
this propose, we consider two outcome variables: (1) LSM2/LSM1
ratio; (2) the cirrhosis progression (F4; LSM ≥ 12.5 kPa)
measured as+1 [if a patient with LSM<12.5 kPa (F≤ 3) changed
to LSM ≥12.5 kPa (F4)] or 0 (if a patient with F ≤ 3 did not
evolve to F4).
Statistical Analysis
To compare independent groups, we used the Mann-Whitney
U test for continuous variables and the Chi-square test or
Fisher’s exact test for categorical variables. In the case of paired
measurements, we used the Sign test for categorical variables and
the Wilcoxon signed-rank test for continuous variables.
We used Generalized Linear Models (GLM) according to
recessive, dominant, and additive inheritance models for the
genetic association study with the aim of comparing the
outcome variables according to MTHFR rs1801133. First, we
used a GLM with a gamma distribution (log-link) to analyze
continuous variables (LSM2/LSM1 ratio) and a GLM with
a binomial distribution (logit-link) to analyze dichotomous
variables (progression to cirrhosis). These tests provide the
arithmetic mean ratio (AMR) or difference between groups, and
the odds ratio (OR) or probability of occurrence of an event.
The most relevant patient characteristics were used to adjust the
GLM tests: gender, age, diabetes, high alcohol intake, injection
drug use, time since HCV diagnosis, HCV genotype, baseline
LSM, time of follow-up, HCV antiviral therapy before baseline
and during the follow-up (patients who failed therapy), and other
SNPs previously described in this study population (PNPLA3
rs738409 (29), MERTK rs4374383 (30), IL7RA rs6897932 (24),
and DARC rs12075 (23). To avoid overfitting the statistical
models, we made a previous selection of covariables with the
Stepwise algorithm, retaining covariables with a p-value < 0.20
at each step.
For all statistical tests, we used the Stata 15.0 (StataCorp,
Texas, USA) and SPSS 24.0 (SPSS INC, Chicago, IL, USA).
Statistical significance was defined as p < 0.05 and all p-values
were two-tailed.
RESULTS
Characteristics of the Patients
The baseline characteristics of our study population are described
in Table 1. HCV-infected patients were 47 years old, around 54%
were males, a low frequency of high alcohol intake (13.5%) or
prior use of intravenous drugs (10.1%). HCV genotype 1 was the
predominant (85.3% of patients), 22.6% of patients previously
failed the interferon therapy, and 71.6% of patients had LSM
< 7.1 kPa. Concerning rs1801133 genotypes, 29 patients were
TT genotype, 112 were CT genotype, and 67 were CC genotype.
No significant differences in baseline characteristics were found
among rs1801133 genotypes, except for prior injection drug
use (p= 0.008).
Characteristics of MTHFR rs1801133
Polymorphism
Table 2 describes the allelic and genotypic frequencies of the
rs1801133 SNP, which showed <5% of missing values, was in
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TABLE 2 | Allelic and genotypic frequencies and Hardy Weinberg Equilibrium test
for MTHFR rs1801133 polymorphism in HCV-infected patients compared to
Iberian population (data from 1,000 Genomes Project Phase 3) (http://grch37.
ensembl.org/index.html).
HCV cohort IBS group P-value
No. 208 107
Alleles T 141 (44.1%) 95 (44.4%) 0.940
C 179 (55.9%) 119 (55.6%)
Genotype TT 29 (13.9%) 18 (16.8) 0.665
CT 112 (53.8%) 59 (55.1%)
CC 67 (32.2%) 30 (28.0%)
HWE (p-value) 0.252 0.241
Statistics: Values are expressed as absolute numbers (%) p-values were estimated with
Chi-squared test.
HCV, hepatitis C virus; HWE, Hardy Weinberg Equilibrium; IBS, Iberian populations in
Spain; MTHFR, methylenetetrahydrofolate reductase.
TABLE 3 | Clinical characteristics related to hepatic fibrosis in patients with
chronic hepatitis C during the follow-up.
All Patients
Characteristic Baseline End P-value
LSM (kPa) 6.1 (5.2; 7.7) 6.8 (5.5; 9.4) <0.001
F0–F1 (<7.1 kPa) 149 (71.6%) 110 (52.9%) <0.001
F2 (7.1–9.4 kPa) 38 (18.3%) 47 (22.6%) 0.382
F3 (9.5–12.4 kPa) 21 (10.1%) 25 (12%) 0.571
F4 (≥12.5 kPa) 0 (0%) 26 (12.5%) <0.001
Statistics: Values are expressed as absolute numbers (%) or median (percentile 25;
percentile 75). P-values were calculated with Sign test for categorical variables and
nonparametric Wilcoxon test for continuous variables.
HCV, hepatitis C virus; kPa, kilopascal; LSM, liver stiffness measurement; F≥ 2, significant
fibrosis; F ≥ 3, advanced fibrosis; F4, cirrhosis.
Significant differences are shown in bold.
Hardy-Weinberg equilibrium (p = 0.252) and had a minimum
allele frequency more than 40%. We compared the genetic
frequencies between patients included in this study and the
Iberian population in Spain (IBS), a population of healthy
subjects published by the 1,000 Genomes Project website (http://
www.1000genomes.org/home). No significant differences were
found for alleles (p= 0.940) or genotypes (p= 0.665).
MTHFR rs1801133 SNP and Related Liver
Fibrosis Progression
The mean follow-up time (the period between the LSM1 and
the LSM2) for all patients was of 46.6 months. In this context,
we found a decrease in the proportion of patients with a low
stage of fibrosis (F0–F1; p < 0.001), whereas both LSM values
and the rate of patients who developed an F4 stage raised
(p < 0.001) (Table 3).
We did not find significant differences among rs1801133
genotypes in the time intervals between the LSM1 and the
LSM2 (48.5 months in TT genotype, 46.9 months in CT
genotype, and 45.5 months in CC genotype; p = 0.921).
We observed decreased values of the LSM2/LSM1 ratio and
the rate of cirrhosis progression in rs1801133 T allele carriers
(Table 4). Moreover, we analyzed the association between
MTHFR rs1801133 polymorphism and liver fibrosis/cirrhosis
progression throughmultivariate GLMs (Table 4, full description
in Supplementary Table 1). The presence of the rs1801133C
allele showed an inverse association with the LSM2/LSM1 ratio
(adjusted AMR = 0.90; 95%CI = 0.83–0.98; p = 0.020) and
the cirrhosis progression (adjusted OR = 0.43; 95%CI = 0.19–
0.95; p = 0.038). Besides, rs1801133 CT/CC genotype had
an inverse association with the LSM2/LSM1 ratio (adjusted
AMR = 0.80; 95%CI = 0.68–0.95; p = 0.009) and the
cirrhosis progression (adjusted OR = 0.21; 95%CI = 0.06–0.74;
p= 0.015) (Table 4).
DISCUSSION
The present study focused on the potential relationship of
MTHFR rs1801133 polymorphism and the development of liver
fibrosis and cirrhosis on HCV-infected patients, using two LSM
values with an interval of at least 12 months. We observed that
CT/CC genotype was related to a decreased risk of progression of
liver fibrosis and the occurrence of cirrhosis.
The C677T genetic substitution at theMTHFR gene results in
the Ala222Val replacement in the MTHFR protein, resulting in a
thermolabile variant associated with lower activity, and therefore,
higher circulating levels of homocysteine (13). Moreover,
MTHFR rs1801133 SNP is in high linkage disequilibrium (LD)
with other MTHFR SNPs, such as A1298C (rs1801131), also
related to a decrease in MTHFR activity (31). The LD between
the two SNPs is strong in the Spanish population (coefficient
of LD = 0.98) (32), so we think that our results may be
extrapolated to the A1298C variant and other MTHFR SNPs
in LD with rs1801133.
The MTHFR rs1801133 SNP was previously linked
to a long list of conditions and diseases, such as
bone disorders, cardiovascular disease, thrombosis,
neurological/neuropsychiatric conditions (33), pre-eclampsia,
diabetes mellitus (34), longevity (35), and several types of
neoplasia (36). Regarding liver diseases, the MTHFR rs1801133
polymorphism is related to altered lipid metabolism (37), which
would contribute to the development of steatosis and fibrosis
in HCV-infected patients (38), as well as the development
of cirrhosis (14, 39–41). Furthermore, in CHC, the MTHFR
rs1801133 variant has also been linked to liver fibrosis/cirrhosis
(16, 17). Toniutto et al. described that recipients with the
presence of MTHFR rs1801133 TT homozygote evolved with
more frequency to a significant fibrosis degree during recurrent
hepatitis C after liver transplantation (16). Similar to this,
Adinolfi et al. described that the T allele is related to a higher
prevalence of steatosis, accelerating the fibrosis development
and liver disease progression (17). These analyses support that
the MTHFR rs1801133 polymorphism and the subsequent
hyperhomocysteinemia are associated with liver fibrosis among
HCV-infected patients. However, there are also other articles
that found no association between the MTHFR rs1801133
variant and liver fibrosis/cirrhosis (19–21). These articles,
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TABLE 4 | Association between MTHFR rs1801133 polymorphism and progression of liver fibrosis in patients with chronic hepatitis C (longitudinal analysis).
MTHFR rs1801133 genotypes Unadjusted Adjusted
Outcome TT CT CC AMR (95%CI) Pa aAMR (95%CI) Pb
LSM2/LSM1
Additive 1.19 (1.00; 1.43) 1.14 (0.95; 1.44) 1.10 (0.89; 1.34) 0.85 (0.77; 0.94) 0.001 0.90 (0.83; 0.98) 0.020
Dominant 1.19 (1.00; 1.43) 1.13 (0.95; 1.43) 0.77 (0.64; 0.93) 0.006 0.80 (0.68; 0.95) 0.009
Progression to F4 TT CT CC OR (95%CI) Pa aOR (95%CI) Pb
Additive 7 (24.10%) 13 (11.60%) 6 (9.00%) 0.55 (0.29; 1.04) 0.069 0.43 (0.19; 0.95) 0.038
Dominant 7 (24.10%) 19 (10.60%) 0.37 (0.14; 0.99) 0.047 0.21 (0.06; 0.74) 0.015
Statistics: Values expressed as absolute numbers (%), median (percentile 25; percentile 75), arithmetic mean ratio (AMR), odds ratio (OR), and 95% of confidence interval (95%CI).
aP-values were calculated by univariate regression; bP-values were calculated by multivariate regression adjusted by the most important clinical and epidemiological characteristics (see
statistical analysis section). Significant differences are shown in bold.
aAMR, adjusted arithmetic mean ratio; aOR, adjusted odds ratio; 95%CI, 95% confidence interval; p-value, level of significance; LSM, liver stiffness measure; F4, cirrhosis; MTHFR,
methylenetetrahydrofolate reductase.
both those that showed an association and those that did not,
had a cross-sectional design, and fibrosis was evaluated by
biopsy. Our article, by contrast, had a longitudinal design that
provides robustness to our data, and liver fibrosis was evaluated
by transient elastography, which has excellent accuracy for
cirrhosis diagnosis.
Other issues should be considered for the correct
interpretation of the data. Firstly, we performed a retrospective
study, which could induce ascertainment and selection biases.
Secondly, the low sample size per group could limit the statistical
power of the tests performed and increasing the rate of false
positives. Therefore, further studies should be conducted to
corroborate our preliminary findings on the potential use
of MTHFR rs1801133 SNP as a predictive marker of liver
fibrosis/cirrhosis progression in HCV-infected patients. Thirdly,
the follow-up time (between LSM1 and LSM2) varied between
different subjects, but 75% of the patients had more than 28
months of follow-up, and globally, all patients presented more
than 12 months of follow-up. Besides, the time of follow-up
in patients stratified by MTHFR rs1801133 genotypes was
comparable. Fourthly, due to the retrospective design of our
investigation, we did not take into account some important
clinical variables, including obesity, abdominal ultrasound,
metabolic syndrome, and pathological study of the liver
(fibrosis, necroinflammation, and steatosis), among others; and
biomarkers, such as HCV viral load, transaminases, platelet
counts, APRI score, and FIB4 index, among others. We did not
have access to these data at the time of the LSM. Moreover, we
had not plasma samples available to measure concentrations of
homocysteine. Finally, we included in the study more than 20%
non-responders to previous interferon therapy, but this HCV
therapy does not seem to protect against the progression of CHC
in the long term studies (42).
CONCLUSION
In summary, in this preliminary study, our data suggest an
association betweenMTHFR rs1801133 SNP and the progression
of liver fibrosis and the development of cirrhosis in HCV-
infected patients. Specifically,MTHFR rs1801133C allele carriers
presented a diminished risk of liver fibrosis progression and
development of cirrhosis than rs1801133 T allele carriers. Further
studies with higher numbers of patients would be needed
to confirm the role of MTHFR in the immune-pathogenesis
of CHC.
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